



DOCKET NO. : GLIS-0064

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Reissue Application of:

Buhr, et al.

U.S. Patent No.: 5,672,697

Issued: September 30, 1997

Serial No.: 652,978

Group Art Unit: 1623 *

Filing Date: February 8, 1991

Examiner: G. Kunz *

For: NUCLEOSIDE 5'-METHYLENE PHOSPHONATES

Assistant Commissioner for Patents
Washington DC 20231

Sir:

CONSENT OF ASSIGNEE FOR REISSUE

and

ASSIGNEE'S STATEMENT OF OWNERSHIP INTEREST IN REISSUE¹

(3.7 3(b))

I. In accordance with 37 CFR §1.172(a), **ISIS Pharmaceuticals, Inc.**, assignee of the entire interest in U.S. Patent No. **5,672,697**, granted on **September 30, 1997**, to inventor(s) **Chris Buhr, Mark Matteucci, Norbert W. Bischofberger, and Brian Froehler**, hereby consents to reissue of said patent for the reasons set forth in the accompanying Reissue Declaration.

II. In accordance with 37 CFR §1.172(a), said assignee of the entire interest in United States Patent No. **5,672,697**, hereby establishes assignee's ownership of said patent and its right to take action therein under 37 CFR §3.73(b) by:

* Enter the Group Art Group and Examiner from which the original patent was issued.

¹ This paper must accompany the application for reissue.

☒ specifying that evidence of said ownership is recorded in the Office for each assignment in the chain of title at Reel 5666 , Frame 0340 and at Reel 9833, Frame 0012.


[Note: list reel and frame for each assignment in chain]

☒ enclosing herewith copies of executed assignment(s) dated February 28, 1991, March 20, 1991 and March 18, 1999 which have been submitted for recording in the Office.

[Note: if other documentation is necessary to show ownership, the Office may require recordation thereof under 37 CFR §2.73(b).]

Date: 9/29/99

ISIS PHARMACEUTICALS, INC.

By: 
B. Lynne Parshall, Esq.
Executive Vice President and
Chief Financial Officer